Abstract
Driven by past successes and the detailed knowledge of signalling cascades and physiological processes, G-protein-coupled receptors are taking a prominent place in the portfolios of many pharmaceutical companies. To successfully address this target class, scientists need not only a good understanding of the specific receptor under investigation, but also the right tools from assay technology, reagent production to a hit-to-lead process that acknowledges the importance of parameters beyond potency and embraces the gain in knowledge of the last decade. This manuscripts attempts to summarise some of the changes and progress made across the pharmaceutical industry to design an efficient and effective strategy for finding and optimising small molecules modulating the activity of GPCRs.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abad-Zapatero C and Metz JT (2005) Ligand efficiency indices as guideposts for drug discovery. DDT 10:464–469
Alanine A, Nettekoven M, Roberts E, Thomas AW (2003) Lead generation – enhancing the success of drug discovery by investing in the hit to lead process. Comb Chem High Through Screen 6:51–66
Austen M, Dohrmann C (2005) Phenotype-first screening for the identification of novel drug targets. DDT 10:275–282
Barak LS, Ferguson SSG, Zhang J, Caron MG (1997) A beta-arrestin green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem 272:27497–27500
Beaumont K, Schmid E and Smith DA (2005) Oral delivery of G protein-coupled receptor modulators: an explanation for the observed class difference. Bioorg Med Chem Lett 15:3658–3664
Bockaert J, Fagni L, Dumuis A, Marin P (2004) GPCR-interacting proteins (GIP). Pharmacol Ther 103:203–221
Caldwell GW, Ritchie DM, Masucci JA, Hageman W, Zhengyin Y (2001) The New Pre-preclinical paradigm: compound optimisation in early and late phase drug discovery. Curr Top Med Chem 1:353–366
Carrithers MD, Marotti LA, Yoshimura A, Lerner MR (1999) A melanophore–based screening assay for Erythropoietin receptors. J Biomol Screen 4:9–14
Clemons PA (2004) Complex phenotypic assays in high-throughput screening. Curr Opin Chem Biol 8:334–338
Davis AM, Keeling DJ, Steele J, Tomkinson NP, Tinker AC (2005) Components of successful lead generation. Curr Topic Med Chem 5:421–439
Di L, Kerns EH (2003) Profiling dug-like properties in discovery research. Curr Opin Chem Biol 7:402–408
Fredriksson R, Schiöth HB (2005) The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharm 67:1414–1425
Glasel JA (2004) Emerging concepts in GPCR research and their implications for drug discovery. Decision Res www.decisionresources.com. Cited 26 November 2006
Grånäs C, Lundholt BK, Heydorn A, Linde V, Pedersen HC, Krog-Jensen C, Rosenkilde MM, Pagliaro L (2005) High content screening for G protein-coupled receptors using cell-based protein translocation assays. Comb Chem High Throughput Screen 8:301–319
Gribbon P, Sewing A (2003) Fluorescence readouts in high throughput screening: no gain without pain? DDT 8:1035–1043
Gribbon P, Sewing A (2005) High-throughput drug discovery: what can we expect from HTS? DDT 10:17–22
Giuliano KA, Haskins JR, Taylor DL (2003) Advances in high content screening for drug discovery. Assay Drug Dev Technol 1:565–577
Hann MM, Oprea TI (2004) Pursuing the lead likeness concept in pharmaceutical research. Curr Opin Chem Biol 8:255–263
Hefti E, Bolten BM (2000) Advances in high throughput screening – do they lead to new drugs? Decision Resources, October 2003, www.decisionresources.com. Cited 26 November 2006
Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Disc 1:727–730
Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. DDT 9:430–431
Jäger S, Brand L, Eggeling C (2003) New fluorescence techniques for high-throughput drug discovery. Curr Pharm Biotechnol 4:463–476
Klabunde T, Hessler G (2002) Drug design strategies for targeting G-protein-coupled receptors. Chem Bio Chem 3:928–944
Klumpp M, Scheel, Lopez-Calle, Busch, Murray J, Pope AJ (2001) Ligand binding to transmembrane receptors on intact cells or membrane vesicles measured in a homogeneous 1-microliter assay format. J Biomol Screen 6:159–170
Kunapili P, Zheng W, Weber M, Solly K, Mull R, Platchek M, Cong M, Zhong Z, Strulovici B (2005) Application of division arrest technology to cell-based HTS: comparison with frozen and fresh cells. Assay Drug Dev Techn 3:17–26
Kuntz ID, Chen K, Sharp KA, Kollman PA (1999) The maximal affinity of ligands. Proc Acad Nat Sci USA 96:9997–10002
Lipinski C, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25
May LT, Avlani VA, Sexton PM, Christopulus A (2004) Allosteric modulation of G protein-coupled receptors. Curr Pharm Des 10:2003–2013
Milligan G (2003) High-content assays for ligand regulation of G-protein coupled receptors. DDT 8:579–585
Milligan G (2004) G protein-coupled receptor dimerisation: function and ligand pharmacology. Mol Pharmacol 66:1–7
Minic J, Sautel M, Salesse R, Pajot-Augy E (2005) Yeast system as a screening tool for pharmaceutical assessment of G protein-coupled receptors. Curr Med Chem 12:961–969
Moore K, Rees S (2001) Cell-based versus isolated target screening: how lucky do you feel? J Biomol Screen 6:69–74
Nambi P, Aiyar N (2003) G protein-coupled receptors in drug discovery. Ass Drug Dev Tech 1:305–310
Nowlin D, Bingham P, Berridge A, Gribbon P, Laflin P, Sewing A (2006) Analysing the output from primary screening. Com Chem High Trough Screen 9:331–337
Peakman T, Franks S, White C, Beggs M (2003) Delivering the power of discovery in large pharmaceutical organisations. DDT 8:203–211
Presland J (2005) Identifying novel modulators of G protein-coupled receptors via interaction at allosteric sites. Curr Opin Drug Disc Dev 8:567–576
Rüdiger M, Haupts U, Moore KJ, Pope AJ (2001) Single-molecule detection technologies in miniaturised high throughput screening: binding assays for G protein-coupled receptors using fluorescence intensity distribution analysis and fluorescence aninsotropy. J Biomol Screen 6:29–37
Sams-Dodd F (2005) Target-based drug discovery: Is something wrong? DDT 10:139–147
Thomsen WJ, Gatlin J, Unett DJ, Behan DP (2004) Developing functional GPCR screens. Curr Drug Disc 1:13–18
Thomsen W, Frazer J, Unett D (2005) Functional assays for screening GPCR targets. Curr Opin Biotech 16:655–665
Wakatsuki T, Fee JA, Elson EL (2004) Phenotypic screening for pharmaceuticals using tissue constructs. Curr Pharm Biotech 5:181–189
Williams C (2004) cAMP detection methods in HTS: selecting the best from the rest. Nat Rev Drug Discov 3:125–135
Williams C, Sewing A (2005) G-protein-coupled receptor assays: to measure affinity or efficacy, that is the question. Comb Chem High Through Screen 8:285–292
Wintner EA, Moallemi CC (2000) Quantized surface complementarity diversity (QSCD): a model based small molecule-target complementarity. J Med Chem 43:1993–2006
Young SS, Lam RLH, Welch WJ (2002) Initial compound selection for sequential screening. Curr Opin Drug Disc Dev 5:422–427
Zuck P, Murray EM, Stec E, Grobler JA, Simon AJ, Strulovici B, Inglese J, Flores OA, Ferrer M (2004) A cell-based b-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication. Ana Biochem 334:344–355
Author information
Authors and Affiliations
Corresponding author
Editor information
Rights and permissions
Copyright information
© 2007 Springer-Verlag
About this paper
Cite this paper
Sewing, A., Cawkill, D. (2007). High-Throughput Lead Finding and Optimisation for GPCR Targets. In: Bourne, H., Horuk, R., Kuhnke, J., Michel, H. (eds) GPCRs: From Deorphanization to Lead Structure Identification. Ernst Schering Foundation Symposium Proceedings, vol 2006/2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/2789_2006_012
Download citation
DOI: https://doi.org/10.1007/2789_2006_012
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-48981-8
Online ISBN: 978-3-540-48982-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)